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ABSTRACT
Introduction: Periadnexal adhesions are
known to contribute to subfertility. The
restoration of the tubo-ovarian anatomy is one
the key principles in reproductive surgery, and
this involves adhesiolysis. However, adhesion
formation/reformation is very common after
periovarian adhesiolysis. It is not known if the
application of Hyalobarrier, an anti-adhesion
gel, around the adnexal region postsurgery
influences ovulatory status. The study is a
pilot randomized controlled trial (RCT)
randomizing women into the application of
Hyalobarrier versus no Hyalobarrier at the
time of laparoscopy, where postsurgical
ovulatory status and pregnancy rates were
evaluated.
Methods: This was a pilot RCT where women
were recruited from the gynecological and
subfertility clinic who were deemed to require
an operative laparoscopy. If intraoperatively they
were found to have periovarian adhesions, they
were randomized into having adhesiolysis with
and without usage of Hyalobarrier.
Demographic details and intraoperative details
including the severity, extent, and the ease of use
of Hyalobarrier were recorded. Prior to the
surgery and postoperatively, the participants had
their serum hormonal status (day 2 FSH, LH and
day 21 progesterone) evaluated. Postoperatively,
they underwent a follicular tracking cycle at
3 months.
Results: Fifteen women were randomized into
use of Hyalobarrier (study group) and 15 into
the no Hyalobarrier group (control group)
between December 2011 and January 2014.
There was no difference in the patient
characteristics in terms of age, BMI, the
number of previous pregnancies, or the extent,
site, and severity of adhesions between the two
groups. There was no significant difference
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between the study versus control groups in
terms of the hormonal profile (day 2 FSH and
day 21 progesterone) before or after surgery. The
3-month postoperative day 10–12 follicular
tracking findings and endometrial thickness
were similar between the study and control
groups. Four women were pregnant in the study
group (24%) and one in the control group (7%)
cumulatively over 2 years.
Conclusion: The use of Hyalobarrier post
salpingo-ovariolysis did not influence follicular
development as inferred from the results of the
day 21 progesterone and folliculogram on day
10–12 3-month postsurgery.
Trial Registration: ISRCTN number,
ISRCTN1833588.
Funding: Nordic Pharma.
Keywords: Adhesiolysis; Fertility; Hyalobarrier;
Ovary; Adhesion prevention
INTRODUCTION
Periadnexal adhesions are adhesions which
envelop the fimbriae ends, the Fallopian tubes,
and/or ovaries. These adhesions can develop
postsurgically, after infection and inflammation
secondary to pelvic inflammatory disease or as a
consequence of other intra-abdominal infective
sources. Periadnexal adhesions contribute to
subfertility by a combination of ways, namely
by the mechanical distortion of the
tubo-ovarian anatomy thereby interfering with
the transport of the ovum into the Fallopian
tube or the disruption of blood supply to the
ovary and its follicular development [1–4].
Indeed, it has been observed that women with
periovarian adhesions are significantly more
prone to have unruptured follicles [5].
The restoration of the tubo-ovarian anatomy
is one of the key principles in reproductive
surgery, and this involves adhesiolysis.
However, adhesion formation/reformation is
very common after periovarian adhesiolysis
(40%) [6]. The natural anatomical position and
density of ovaries preclude the hydrofloatation
mechanism as an effective adhesion prevention
strategy after adnexal surgery [7]. Hence,
consideration is required for the application of
other forms of adhesion prevention agents such
as hyaluronic gel-based products.
Hyalobarrier Gel Endo is a sterile,
transparent, and highly viscous gel that forms a
barrier to prevent or reduce postsurgical
adhesions. A recent randomized controlled trial
(RCT) examining if the intrauterine instillation
of Hyalobarrier after the evacuation of products
of conception showed a significant reduction in
the formation of intrauterine adhesions
postoperatively at second-look hysteroscopy
[8]. The gel is composed of highly purified,
auto-crosslinked polymers of hyaluronic acid.
Hyaluronic acid is a main component of the
connective tissue in the human body. When
applied between tissue surfaces, it ensures that
adhesive surfaces of the peritoneum in the
ovarian fossae are separated and thus is
theoretically effective in periovarian
postoperative adhesion prevention. Within the
peritoneum, this gel-based product is required to
be placed on and adjacent to the ovaries and
Fallopian tubes, and the immediate impact on
ovulatory function and subsequent reproductive
outcome is unclear.
The study is a pilot RCT randomizing women
into the application of Hyalobarrier versus no
Hyalobarrier at the time of laparoscopy once
the surgeon confirmed the presence of
salpingo-ovarian adhesions and proceeded to
perform salpingo-ovariolysis. The ovarian
function of women with periovarian
adhesiolysis who had Hyalobarrier as an
anti-adhesion barrier instilled and those who
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did not was compared. The clinical pregnancy
rates of the two groups of women were also
evaluated at 2 years postoperatively.
METHODS
Thiswas apilot RCTwherewomenwere recruited
from the gynecological and subfertility clinic
who were deemed to require an operative
laparoscopy. If intraoperatively they were
found to have periovarian adhesions, they were
randomized into having adhesiolysis with
Hyalobarrier (study group) and without usage
of Hyalobarrier (control group).
The inclusion criteria were (1) age
18–38 years; (2) women undergoing operative
laparoscopy for gynecological pathology, with
possible periovarian adhesions. The exclusion
criteria were the (1) presence of malignancies or
a history of malignancies; (2) women on
medications that affected ovulation; and (3)
women with known conditions that resulted in
anovulation (PCOS, pituitary causes).
The method of conduct of this RCT is similar
to studies previously conducted by our group
[9]. Randomization was performed using
computer-generated random numbers and the
concealed, opaque, unlabeled envelope was
opened after it had been determined that the
patient met the intraoperative criteria. The
patients were blinded to the allocation of
treatment, and the assessor during follow-up
was blinded to the treatment. The assessor who
administered the questionnaires and recruited
the patients was the research nurse who did not
have prior knowledge of what type of surgery
the patients underwent. Consent was obtained
prior to any baseline assessments. The operation
notes were stored in a sealed envelope within
the patient notes and not accessed except
during an emergency. In the latter case, the
data would be used to the point of unblinding.
The randomization code was broken at the end
of the follow-up period, and patients who
wished to know were informed of their
treatment groups.
Laparoscopic surgeons who were skilled in
advanced laparoscopy performed the surgery.
Entry into the abdomen was either via the
traditional Veress needle or a modified Hasson’s
technique of open entry. CO2 was used for
creating a pneumoperitoneum of 20 mmHg
before a 10-mm trocar was inserted into the
intraumbilical incision. Two or three more
lateral ports were inserted depending on the
site and extent of surgery. During surgery, the
principles of microsurgery were followed,
including meticulous hemostatic control and
usage of constant irrigation to prevent tissue
desiccation. Hyalobarrier was applied to
women randomized intraoperatively to the
study group, and no Hyalobarrier was applied
to the group randomized to the control group.
Ten milliliters of Hyalobarrier Gel Endo was
applied using the standard applicator in the
commercial pack over the operative site(s). A
short questionnaire on the ease of use of the
Hyalobarrier was completed by the surgeon
postoperatively. The questions included were
(1) if the gel was applied, (2) the ease of
application during surgery (range from very
poor, poor, fair, good, and very good), (3) if the
surgeons would use the gel again in the next
appropriate surgery, and (4) any other general
feedback.
The patients’ histories, clinical examination,
and operative findings were documented on
standard proforma. The extent, severity, and
site of adhesions were noted and the
completeness of adhesiolysis was documented.
The extent of the adhesions was defined as no
adhesions, mild (adhesions covering less than
26% of total area), moderate (adhesions
covering 26–50% of total area), and severe
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(adhesions covering at least 51% of total area).
The severity of adhesions was defined as no
adhesions, mild (filmy and avascular
adhesions), moderate (some vascularity and/or
dense adhesions), and severe (cohesive)
adhesions. All patients’ data and including
hormonal and follicular tracking results were
entered into a computerized database.
Complications during and after the surgery
were documented on standard proforma sheets.
Prior to the surgery, and postoperatively, the
participants had their serum hormonal status
(day 2 FSH, LH and day 21 progesterone)
evaluated. Postoperatively, they underwent a
follicular tracking cycle at 3 months. Ovulation
was compared as a continuous outcome of day
21 progesterone levels with follicular scan
performed on day 10–12 used as supportive
evidence. The patient flow of this trial is as per
Fig. 1.
Statistical Analysis
Given that adhesion reformation is significant
after adnexal surgery (up to 90%), taking the
mean of day 21 progesterone (±SD) for the
control group to be 33 (7) nmol/l and the study
group to be 51 (15.7) [5], the sample size for
each group required to show a statistical
significance at the p = 0.05 level between the
study and control groups was calculated to be
n = 15 (total sample size = 30).
The outcome measures were postoperative
day 2/3 FSH, LH, day 21 progesterone, evidence
of follicular development during follicular
tracking at day 10–14, and clinical pregnancy
defined as the presence of a fetal heart at the
6-week scan.
The data analysis was performed using SPSS.
T test comparisons will be used for continuous
variables, and Chi2 for discrete variables.
Compliance with Ethics Guidelines
The ethics number of this study was 11/H0504/
6 and the ISRCTN number was ISRCTN1833588.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Declaration of Helsinki (1964), as revised in
2013. Informed consent was obtained from all
patients for being included in the study.
This research conformed to the CONSORT
guidelines.
RESULTS
A total of 43 women were screened and 15 were
randomized into the study group and 15 into
the control group between December 2011 and
January 2014. There was no difference in theFig. 1 Flow diagram showing the patient ﬂow of the trial
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patient characteristics (Tables 1, 2, 3) in terms of
age, BMI, the number of previous pregnancies,
or the extent, site, and severity of adhesions
between the two groups. None of the patients
had endometriosis.
There was no significant difference in the
mean ± SD between the study versus control
groups in terms of the hormonal profile (day 2
FSH and day 21 progesterone) before or after
surgery (Table 3). The 3-month postoperative
day 10–12 follicular scan showed similar
development of mature follicles in the study
group (mean diameter of follicle
18.1 ± 3.9 mm) and the control group (mean
diameter of follicle 19.8 ± 5.6 mm). There was
also no difference in the endometrial thickness
in the study (10.4 ± 2.2 mm) versus the control
group (8.7 ± 0.6 mm) at the 3-month scan
postoperatively (see Table 4).
Four womenwere pregnant in the study group
(24%) and one in the control group (7%)
cumulatively over 2 years. Amongst the
pregnant patients in the study group, there were
three spontaneouspregnancieswithin18 months
postsurgery and one pregnancy following an
in vitro fertilization (IVF) treatment. In the
control group, one woman was spontaneously
pregnant within 12 months of surgery.
The majority of surgeons reported that the
Hyalobarrier Gel Endo was easy to apply. There
was one questionnaire which was not returned.
DISCUSSION
The use of Hyalobarrier post
salpingo-ovariolysis did not influence follicular
development as inferred from the results of the
day 21 progesterone and folliculogram on day
10–12 3-month postsurgery. This finding will
need to be confirmed in larger studies; however,
preliminary data suggests that the application
of the Hyalobarrier is not detrimental to
follicular development as denoted by follicular
scan and hormonal evaluation postoperatively.
Reproductive surgeons and gynecologists are
often confronted with the conundrum of
whether or not to remove adhesions around
the adnexal area involving the Fallopian tubes
and ovaries, in the presence of apparently
patent Fallopian tubes. This dilemma is in part
resolved with the advent of IVF technology,
where fully functional Fallopian tubes are not
required for conception, and hence
intraoperatively, if IVF was thought to be a
viable option for the patient, that their adnexal
adhesions are often left unlysed to save
operative time and unnecessary operative
complications. Unfortunately, whilst IVF offers
a real and tangible option for a successful
conception, the pregnancy rate per cycle is
stagnated at around 30% per cycle (Human
Fertilisation and Embryology Authority, HFEA).
The UK National Health Service (NHS) publicly







Age (mean ± SD) 32.7 ± 4.7 31.5 ± 3.8 NS
BMI (mean ± SD) 23.4 ± 2.8 24.0 ± 3.9 NS
Number of previous surgeries (mean ± range) 0.8 (0–5) 0.8 (0–4) NS
Number of previous pregnancies (mean ± range) 0.9 (0–4) 1.1 (0–9) NS
NS not signiﬁcant
Adv Ther (2017) 34:199–206 203
funds limited numbers of IVF cycles. The cost of
a private cycle of IVF often prohibits a
significant number of patients accessing this
treatment for conception. This means that in
real terms, about two-thirds of patients who did
not manage to achieve a pregnancy after their
IVF treatment will continue to suffer from
infertility. The latter further emphasizes the
complementary nature of surgery to IVF.
Traditionally in reproductive surgery,
adnexal adhesions can be managed by
adhesiolysis. It has been reported that the
cumulative pregnancy rate 1 year after
adhesiolysis can be as high as 67%, although a
substantial number of patients were observed to
have adhesion reformation at second-look
laparoscopy [10]; but the increased risk of
ectopic pregnancy remains high, especially if
salpingostomy was also performed [11].
However, there are few data on the effects of
these agents on fertility and pregnancy
outcomes whether when applied
intra-abdominally or intrauterine [12]. Very
often, RCTs on these agents evaluate end
points pertaining to adhesion reformation
rather than pregnancy outcomes [13]. No
studies have examined the postsurgical
ovulatory status, endometrial thickness, and






Bladder 2 2 NS
Posterior uterus 3 2 NS
Adnexal adhesions 51 53 NS
NS not signiﬁcant
Table 3 Severity and extent of adhesions in the comparison groups







Table 4 Hormonal and ultrasound results in the Hyalobarrier and no Hyalobarrier groups
Patient characteristics Hyalobarrier No Hyalobarrier Signiﬁcance
Presurgery day 2 FSH 7.2 ± 2.4 6.24 ± 1.5 0.22
Presurgery day 21 progesterone 27.3 ± 14.8 32.2 ± 17.5 0.31
Postsurgery FSH 6.2 ± 1.7 4.5 ± 1.0 0.19
Postsurgery day 21 progesterone 17.4 ± 13.3 24.1 ± 11.3 0.37
Postsurgery day 10–12 follicular scan 18.1 ± 3.9 19.8 ± 5.6 0.78
Postsurgery endometrial thickness 10.4 ± 2.2 8.7 ± 0.6 0.28
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the clinical pregnancy rates after application of
the anti-adhesion gel around the adnexal
region(s). Our study suggests that there is no
difference between the ovulatory status and
endometrial development of women who had
the Hyalobarrier gel applied intraoperatively
versus those who had not, as observed from day
21 progesterone hormonal profile and follicular
tracking scans performed at 3 months
postoperatively.
Whilst this study did not provide
second-look adhesion formation data,
adhesion formation post application of the
Hyalobarrier gel has been evaluated after
other forms of gynecological surgery [8, 14]
with some evidence of benefit. As the
anti-adhesion gel is easy to use, surgeons
should consider the application of
anti-adhesion treatment around the adnexal
region after salpingo-ovariolysis and
adhesiolysis in relation to adhesive pelvic
disorders [15, 16] to reduce the incidence of
postoperative adhesions.
The limitations of this study include the
small sample size. Future larger RCTs powered
to assess pregnancy rates and time to pregnancy
as the primary endpoint will be important to
further evaluate the fertility aspects of using
anti-adhesion barriers following
salpingo-ovariolysis and adhesiolysis in
relation to adhesive pelvic disorders.
CONCLUSION
Preliminary data suggests that the application
of the Hyalobarrier is not detrimental to
follicular development as denoted by follicular
scan and hormonal evaluation postoperatively.
Surgeons should consider the application of
anti-adhesion treatment around the adnexal
region after salpingo-ovariolysis and
adhesiolysis in relation to adhesive pelvic
disorders to reduce the incidence of
postoperative adhesions.
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